Cocrystal Pharma, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Bothell WA United States (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2016
NCT02760758
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cocrystal Pharma, Inc.

Active Ingredients

Drugs in Phase 2 Trials (6)

Key: Cocrystal Pharma, Inc. (3) Acquired (3)

amdoxovir (3 trials)

cc-42344 (2 trials)

sofosbuvir (sovaldi) (1 trial)

tenofovir (viread) (1 trial)

velpatasvir (Epclusa) (2 trials)

zidovudine (retrovir) (1 trial)

Drugs in Phase 1 Trials (1)

cdi-988 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 7